Sarepta presents preclinical SRP-1003 data in DM1
The company presented data at the 2026 Oligonucleotide Therapeutics Society Annual Meeting showing robust knockdown of pathogenic DMPK RNA in the nucleus with SRP-1003.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP — 1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
For best results when printing this announcement, please click on link below: Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting Correction of MBNL- dependent mis-splicin
Sarepta Presents Preclinical SRP-1003 Data in DM1
Sarepta said it presented preclinical data on SRP-1003 at the Oligonucleotide Therapeutics Society annual meeting, reporting robust knockdown of pathogenic DMPK RNA in the nucleus.